Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma | Zendy

Yohann Loriot | Zendy; Andrea Necchi | Zendy; Se Hoon Park | Zendy; Jesús García-Donás | Zendy; Robert Huddart | Zendy; Earle F. Burgess | Zendy; Mark T. Fleming | Zendy; Arash Rezazadeh | Zendy; Begoña Mellado | Zendy; Sergey Varlamov | Zendy; Monika Joshi | Zendy; Ignacio Durán | Zendy; Scott T. Tagawa | Zendy; Yousef Zakharia | Zendy; Bob Zhong | Zendy; Kim Stuyckens | Zendy; Ademi Santiago-Walker | Zendy; Peter De Porre | Zendy; Anne O’Hagan | Zendy; Anjali Narayan Avadhani | Zendy; Arlene O. SiefkerRadtke | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Author(s) -

Yohann Loriot,

Andrea Necchi,

Se Hoon Park,

Jesús García-Donás,

Robert Huddart,

Earle F. Burgess,

Mark T. Fleming,

Arash Rezazadeh,

Begoña Mellado,

Sergey Varlamov,

Monika Joshi,

Ignacio Durán,

Scott T. Tagawa,

Yousef Zakharia,

Bob Zhong,

Kim Stuyckens,

Ademi Santiago-Walker,

Peter De Porre,

Anne O’Hagan,

Anjali Narayan Avadhani,

Arlene O. SiefkerRadtke

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1817323

Subject(s) - urothelial carcinoma , metastatic urothelial carcinoma , medicine , oncology , urology , cancer , bladder cancer

Alterations in the gene encoding fibroblast growth factor receptor ( FGFR ) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase inhibitor of FGFR1-4, has shown antitumor activity in preclinical models and in a phase 1 study involving patients with FGFR alterations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research